Investing.com - Exelixis reported on Monday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Exelixis announced earnings per share of $0.35 on revenue of $451.14M. Analysts polled by Investing.com anticipated EPS of $0.25 on revenue of $446.42M.
Exelixis shares are down 29.2% from the beginning of the year and are trading at $15.68 , down-from-52-week-high.
Exelixis follows other major Healthcare sector earnings this month
Exelixis's report follows an earnings beat by Merck ADR on Friday, September 9, 2022, who reported EPS of $0.5392 on revenue of $5.69B, compared to forecasts EPS of $0.5165 on revenue of $5.57B.
Carl Zeiss Meditec ADR had beat expectations on Friday, September 9, 2022 with fourth quarter EPS of $0.7134 on revenue of $486.54M, compared to forecast for EPS of $0.7116 on revenue of $486.31M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar